Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 2/20 | 0.32 |
| ▸ | CDK8 | P49336 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328132 | 1.00 | MAPK14 (0.39) | MAPK14ESR1TDO2MAPTESR2 | |
| SCHEMBL3326373 | 0.90 | CCNC (0.35) | ESR1MAPTCCNCCDK8NR4A2 | |
| SCHEMBL3326376 | 0.90 | CCNC (0.35) | ESR1MAPTCCNCCDK8NR4A2 | |
| SCHEMBL3327333 | 0.81 | PTPN1 (0.36) | MAPK14ESR1TDO2MAPTESR2 | |
| SCHEMBL3327323 | 0.81 | PTPN1 (0.36) | MAPK14ESR1TDO2MAPTESR2 | |
| SCHEMBL3607851 | 0.80 | MAPK14 (0.61) | MAPK14CA12ALPLRPA1NR4A2 | |
| SCHEMBL3328685 | 0.78 | KMT2A (0.35) | MAPTCCNCCDK8 | |
| SCHEMBL3328679 | 0.78 | KMT2A (0.35) | MAPTCCNCCDK8 | |
| SCHEMBL3601024 | 0.75 | MAPK14 (0.42) | MAPK14ESR1MAPTESR2PTGS2 | |
| SCHEMBL3328430 | 0.74 | TBXAS1 (0.38) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | NAT1, NAPEPLD, NR1I2 | MAPK14 4071/4885ESR1 1427/4885TDO2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.